In a subset analysis, a BSA of least 76% was associated with AD (aOR, Table 2) . Itching or burning was associated with all 4 atopic diseases (P < .001).
sults are consistent with those of a previous study of 59 patients with vitiligo that found increased rates of asthma, hay fever, and positive results from skin prick and radiosorbent allergen testing. 7 Similarly, a Chinese study of 6516 patients with vitiligo found a higher prevalence of asthma in familial probands.
8
History of atopic disease may be helpful to predict which patients with vitiligo will experience progression to extensive disease. There are several possible explanations for the association of vitiligo involving a BSA of at least 76% and itching or burning with atopic diseases. The proinflammatory state of AD may predispose toward melanocyte destruction, while scratching of pruritic AD lesions may koebnerize vitiligo. Alternatively, there may be a common genetic mutation(s) that predisposes to both AD and vitiligo. One such example might be vitamin D receptor polymorphisms that are associated with generalized vitiligo and severe AD.
9 Filaggrin mutations are thought to mediate severity for patients with alopecia areata and with AD and should be explored in vitiligo. 10 This raises an important question: does atopy predispose toward vitiligo or do the 2 diseases merely coexist? This study has several strengths, including being prospective with a validated survey instrument for vitiligo. However, it is limited by the lack of a control group without vitiligo. A large randomized sample of healthy patients with minimization of bias should be used for controls. However, that is a very ambitious undertaking, beyond the scope of this pilot study, and will be the subject of future studies. Letters systematic assessment, those found to be colonized were offered decolonization therapy with rifampin, 300 mg twice daily; doxycycline, 100 mg twice daily; mupirocin, 2%, ointment thrice daily to the nares and perineal region for 1 week; and daily chlorhexidine gluconate showers for 7 days (thrice weekly recommended indefinitely thereafter). Patients without cultures that were positive for S aureus were offered the same decolonization therapy if clinical suspicion for colonization was high based on the patient's medical history (ie, recurrent boils or folliculitis). For patients treated with decolonization therapy, we collected demographic, clinical, and laboratory data in the 12 months prior to consultation and after decolonization. This study was reviewed by the OHSU institutional review board and was approved with a waiver of informed consent and Health Insurance Portability and Accountability Act research authorization.
Implications for
Results | We identified 19 patients referred to the ID clinic by our rheumatology or dermatology clinics for SSTIs in the context of prior or planned immunosuppressive therapy. At the time of consult, 16 patients (84%) were colonized with S aureus and 15 (79%) were actively receiving immunosuppressive therapy (Table 1) . Nine (53%) reported household pet contacts in the 12 months prior to decolonization. Seventeen (90%) were prescribed decolonization therapy (Table 1 ). All patients reported adherence to their regimen without adverse events. Sixteen (90%) initiated or resumed immunosuppressive therapy after decolonization ( Table 2) and had ongoing follow-up within referring specialty clinics for a mean of 17 months (range, 1-47 months) after decolonization. Four patients (24%) had recurrent SSTI postdecolonization (incidence rate, 1.6 per 100 person-years).
Discussion | We report our clinical experience in providing S aureus decolonization therapy for patients with SSTI in whom biologic therapy was either interrupted or planned. All patients successfully completed decolonization, and most subsequently remained infection-free for long time periods despite resuming or initiating biologic or other immunosuppressive therapy. Our results suggest that decolonization therapy could be useful in preventing SSTIs in such patients, potentially affording them less infectionrelated treatment interruptions in their immunosuppressive therapies.
The decolonization regimen used in this study has been previously reported to be effective, although 50% of such patients in prior studies are known to become recolonized at 6 months after therapy, likely owing to contact with colonized household members or other close contacts.
4 Several methods to eradicate S aureus colonization have been published, although most patients experience a high rate of recolonization or a lack of long-term follow-up. A recent open-label trial 5 evaluating hygiene education, intranasal mupirocin, and bleach baths observed a 71% success rate in decolonization at 4 months after therapy. Given the retrospective nature of our cases series and lack of a comparator group, we are limited in drawing firm conclusions regarding the effectiveness of S aureus decolonization in this setting. However, nearly all patients in our series were followed subsequently in their referring clinics and systematically reevaluated for SSTI recurrence. The incidence rate of recurrent SSTI in this small group of decolonized individuals was low, at least compared with that observed in other population-based studies of patients with RA. 1, 6 While it seems plausible, it is unclear if biologic therapy increases SSTI risk in patients colonized with S aureus and whether such patients benefit from decolonization. However, for those with recurrent SSTIs causing interruption in biologic therapy decolonization therapy might facilitate continued use of biologic therapy. 
